Macquarie Group Ltd. maintained its position in shares of XOMA Corporation (NASDAQ:XOMA) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 40,000 shares of the biotechnology company’s stock at the close of the second quarter. Macquarie Group Ltd. owned 0.53% of XOMA Corporation worth $280,000 at the end of the most recent reporting period.
Separately, California Public Employees Retirement System lifted its position in XOMA Corporation by 95.5% during the first quarter. California Public Employees Retirement System now owns 21,780 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 10,640 shares in the last quarter. 32.92% of the stock is owned by institutional investors.
Several equities analysts recently weighed in on the company. Zacks Investment Research downgraded XOMA Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, August 15th. Wedbush reiterated a “hold” rating on shares of XOMA Corporation in a research report on Monday, August 14th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of XOMA Corporation in a research report on Thursday, August 10th. Finally, ValuEngine upgraded XOMA Corporation from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. XOMA Corporation presently has an average rating of “Hold” and a consensus price target of $27.33.
COPYRIGHT VIOLATION WARNING: “Macquarie Group Ltd. Has $280,000 Position in XOMA Corporation (XOMA)” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://sportsperspectives.com/2017/11/02/macquarie-group-ltd-has-280000-position-in-xoma-corporation-xoma.html.
XOMA Corporation Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.